Relief Therapeutics (OTC: RLFTF) may not be a particularly well-known company but in recent times the company has seen its stock make considerable due to its work on a coronavirus medicine.
The biopharmaceutical company is working on a product named RLF 100 which is meant for treating and currently it is at an advanced stage. Relief is collaborating with NeuroRx for the development of the product and back in February, there was a positive announcement. Hence, it was no surprise that the stock Relief stock jumped considerably on the back of the announcement, and over the past days, the stock has been in consolidation mode.
The product, which is meant for treating patients suffering from severe symptoms of COVID 19, showed positive effects on patients in the Phase 2b/3 trial. Considering the fact that the coronavirus pandemic is far from over, it might be a good idea for investors to keep a closer eye on the Relief stock over the coming days.